Propanc Biopharma, Inc. (PPCB) Stock Analysis & Investment Frameworks
Propanc Biopharma, Inc. (PPCB) stock analysis on Invetso. Review Propanc Biopharma, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Propanc Biopharma, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: AU
Propanc Biopharma, Inc. Key Financial Metrics
- Market Cap: $779203.00
- Revenue: $N/A
- ROE: -167.51%
- ROIC: -183.49%
- Dividend Yield: N/A
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
Propanc Biopharma, Inc. Investment Frameworks
Invetso analyzes Propanc Biopharma, Inc. (PPCB) across the following frameworks:
- Propanc Biopharma, Inc. 10Y Growth Potential
- Propanc Biopharma, Inc. Scenario Analysis
- Propanc Biopharma, Inc. Risks & Opportunities
- Propanc Biopharma, Inc. Economic Moat
- Propanc Biopharma, Inc. Business Model
- Propanc Biopharma, Inc. Management
- Propanc Biopharma, Inc. SWOT Analysis
- Propanc Biopharma, Inc. Porter's 5 Forces
- Propanc Biopharma, Inc. PESTLE Analysis
- Propanc Biopharma, Inc. ESG Analysis